These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15857402)

  • 1. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo.
    Eyüpoglu IY; Hahnen E; Buslei R; Siebzehnrübl FA; Savaskan NE; Lüders M; Tränkle C; Wick W; Weller M; Fahlbusch R; Blümcke I
    J Neurochem; 2005 May; 93(4):992-9. PubMed ID: 15857402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures.
    Xu J; Sampath D; Lang FF; Prabhu S; Rao G; Fuller GN; Liu Y; Puduvalli VK
    J Neurooncol; 2011 Nov; 105(2):241-51. PubMed ID: 21598070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model.
    Ugur HC; Ramakrishna N; Bello L; Menon LG; Kim SK; Black PM; Carroll RS
    J Neurooncol; 2007 Jul; 83(3):267-75. PubMed ID: 17310267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
    Ogawa T; Hayashi T; Tokunou M; Nakachi K; Trosko JE; Chang CC; Yorioka N
    Cancer Res; 2005 Nov; 65(21):9771-8. PubMed ID: 16266998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
    Zhang C; Richon V; Ni X; Talpur R; Duvic M
    J Invest Dermatol; 2005 Nov; 125(5):1045-52. PubMed ID: 16297208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.
    Eyüpoglu IY; Hahnen E; Tränkle C; Savaskan NE; Siebzehnrübl FA; Buslei R; Lemke D; Wick W; Fahlbusch R; Blümcke I
    Mol Cancer Ther; 2006 May; 5(5):1248-55. PubMed ID: 16731757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suberoylanilide hydroxamic acid represses glioma stem-like cells.
    Hsu CC; Chang WC; Hsu TI; Liu JJ; Yeh SH; Wang JY; Liou JP; Ko CY; Chang KY; Chuang JY
    J Biomed Sci; 2016 Nov; 23(1):81. PubMed ID: 27863490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study.
    Yang XF; Zhao ZJ; Liu JJ; Yang XH; Gao Y; Zhao S; Shi S; Huang KQ; Zheng HC
    Oncotarget; 2017 Jan; 8(2):3156-3169. PubMed ID: 27911270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
    Sato A; Asano T; Ito K; Sumitomo M; Asano T
    BJU Int; 2012 Apr; 109(8):1258-68. PubMed ID: 21895936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
    Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
    Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
    Chien CW; Yao JH; Chang SY; Lee PC; Lee TC
    Toxicol Appl Pharmacol; 2011 Nov; 257(1):59-66. PubMed ID: 21889949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells.
    Zhang S; Huang WB; Wu L; Wang LY; Ye LB; Feng BH
    Asian Pac J Cancer Prev; 2014; 15(10):4331-8. PubMed ID: 24935393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells.
    Komatsu N; Kawamata N; Takeuchi S; Yin D; Chien W; Miller CW; Koeffler HP
    Oncol Rep; 2006 Jan; 15(1):187-91. PubMed ID: 16328054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
    Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
    Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
    Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
    BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of radiation response by histone deacetylase inhibition.
    Chinnaiyan P; Vallabhaneni G; Armstrong E; Huang SM; Harari PM
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):223-9. PubMed ID: 15850925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.
    Kisseberth WC; Murahari S; London CA; Kulp SK; Chen CS
    Am J Vet Res; 2008 Jul; 69(7):938-45. PubMed ID: 18593248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.